• Uttara Saran, Balaji Chandrasekaran, Venkatesh Kolluru, Ashish Tyagi, Kristy D Nguyen, Crystal L Valadon, Saad P Shaheen, Maiying Kong, Triparna Poddar, Murali K Ankem, and Chendil Damodaran.
• Department of Urology, University of Louisville, Louisville, KY.
• Transl Res. 2021 May 1; 231: 9210192-101.

AbstractCurrently, clinicians rely on clinical nomograms to stratify progression risk at the time of diagnosis in patients with prostate cancer (CaP). However, these tools may not accurately distinguish aggressive potential in low-grade CaP. The current study determined the diagnostic potential of 3 molecular markers (ROCK1, RUNX3, and miR-301a) in terms of their ability to identify which low-grade tumors are likely to progress. Real-time PCR and immunohistochemical analysis were used to assess ROCK1, RUNX3, and miR-301a expression profiles in 118 serum and needle biopsy specimens. Expressions of ROCK1 and miR-301a were found to be significantly higher in Gleason 6 and 7 CaP as compared to BPH, while an inverse trend was observed with RUNX3. Further, incorporation of all 3 molecular markers significantly improved clinical nomograms' diagnostic accuracy and correlated with disease progression. Hence, in conclusion, the inclusion of these 3 molecular markers identified aggressive phenotype and predicted disease progression in low-grade CaP tumors at the time of diagnosis.Copyright © 2020 Elsevier Inc. All rights reserved.

25 keywords...

hide…